Elizabeth R Brown, DO
Obstetrics/Gynecology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 11
- 2 carriers
- Office
- 1
- Since medical school
- 15 years
- West Virginia School of Osteopathic Medicine, 2011
Offices
1 location · Regents Univ of California UCSF · 276 clinicians in this group
Looking this up.
Hospitals listed: Marinhealth Medical Center. That is not proof they admit you there this week.
Plans that list them
11 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Brown’s office at (415) 476-1000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
11 of 11 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Marinhealth Medical CenterGreenbrae, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of MarinHealthPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.66 (3.59 to 7.73) · 1,505 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.177, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025
See every measure and the patient survey for Marinhealth Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 3 better, 8 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.66 (3.59 to 7.73) · 1,505 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.177 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.85 (0 to 1.83) · 1,056 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.04 (0.72 to 1.36) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.34 (112.58 to 222.09) · 57 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 47 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.5 · 119 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.6 · 257 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 428 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.4 · 477 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 197 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,827 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.38) · 6,990 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.41) · 6,838 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.41 (0 to 3) · 664 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.86 (1.4 to 4.33) · 1,436 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.38 (3.68 to 17.08) · 705 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.38 (0.72 to 8.04) · 672 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.66 (0.18 to 3.15) · 300 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.56 (0 to 1.25) · 5,550 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 76 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.396 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 275 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 427 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -20.3 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 3.3 · 494 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -4.9 · 499 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.9 · 435 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (3.6 to 8.4) · 93 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.2 (7.8 to 16) · 93 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.6 · 84 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 111 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (10.3 to 16.5) · 2,119 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.4) · 670 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,233 patients answered, 19% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 68% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 48% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
Original Medicare doctor bills
$14,946
Medicare paid this office $14,946 for 110 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 59 | $4,835 | $76 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 58 | $2,615 | $45 |
| Return visit (30+ min) | 14 | $1,453 | $97 |
| New patient visit (30+ min) | 12 | $805 | $67 |
Procedures Medicare counted
| Removal of the uterus | 1-10 | None |
Who their Medicare patients are
110 Original Medicare patients in 2024. Average age 73 · Women 100% · Health risk score 0.65. At or below the middle of the specialty; the typical obstetrics & gynecology clinician is at 0.88.
Conditions among them: High blood pressure 37% · Cancer 15% · Depression 15% · Coronary heart disease 12%.
The office billed $111,966, Medicare allowed $19,516 and paid $14,946; for 197 services of 19 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 110 | 197 | 73 | 0.65 | $111,966 | $14,946 |
| 2023 | 103 | 166 | 73 | 0.67 | $85,670 | $11,455 |
| 2022 | 90 | 126 | 72 | 0.75 | $48,326 | $8,858 |
| 2021 | 65 | 89 | 69 | 0.69 | $49,669 | $5,952 |
| 2020 | 60 | 80 | 71 | 0.82 | $30,729 | $4,341 |
| 2019 | 91 | 142 | 71 | 0.73 | $89,893 | $9,256 |
| 2018 | 90 | 160 | 72 | 0.98 | $26,871 | $7,982 |
| 2017 | 94 | 159 | 70 | 0.85 | $25,477 | $9,469 |
| 2016 | 109 | 178 | 73 | 0.74 | $22,782 | $9,108 |
| 2015 | 27 | 38 | 70 | 0.67 | $5,856 | $2,469 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Short return visit (20+ min) | 56 | $4,153 | $74 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 42 | $1,888 | $45 |
| New patient visit (30+ min) | 11 | $1,107 | $101 |
| Return visit (30+ min) | 11 | $920 | $84 |
2022: 2 services
| Short return visit (20+ min) | 37 | $3,341 | $86 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 41 | $1,809 | $44 |
2021: 2 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 38 | $1,717 | $45 |
| New patient visit (30+ min) | 11 | $1,018 | $93 |
2020: 2 services
| Short return visit (20+ min) | 23 | $1,475 | $59 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 18 | $806 | $45 |
2019: 2 services
| Short return visit (20+ min) | 33 | $2,152 | $60 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 29 | $1,262 | $44 |
2018: 4 services
| Short return visit (20+ min) | 24 | $1,680 | $60 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 36 | $1,578 | $44 |
| Short return visit | 17 | $818 | $37 |
| Urinalysis, manual test | 14 | $51 | $3 |
2017: 4 services
| Short return visit (20+ min) | 18 | $1,288 | $59 |
| Short return visit | 25 | $1,133 | $35 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 25 | $1,099 | $44 |
| New patient visit (15+ min) | 11 | $567 | $52 |
2016: 5 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 43 | $1,882 | $44 |
| Short return visit (20+ min) | 24 | $1,319 | $55 |
| Short return visit | 26 | $1,042 | $35 |
| New patient visit (30+ min) | 11 | $812 | $74 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 15 | $799 | $53 |
2015: 1 service
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 13 | $571 | $44 |
Medicaid work
$2,797 in 2024
Medicaid paid $2,797 for 93 billed services this clinician did in 2024, up to 16 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Ultrasound, pregnant uterus, real time with image documentation, limited (eg, fetal heart beat, placental location, fetal position and/or qualitative amniotic fluid volume), 1 or more fetuses | 42 | $1,891 |
| FETAL NON-STRESS TEST | 51 | $907 |
| 2024 | 93 | 2 | 16 | $2,797 |
Drugs they prescribed that Part D paid
$31,883
Pharmacies billed $31,883 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
224 generic and 49 brand-name prescriptions · $31,883 in drug cost · 12 antibiotic prescriptions to 12 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Estradiol | 82 | $5,471 | $67 |
| Premarin | 13 | $5,438 | $418 |
| Yuvafem | 26 | $4,641 | $178 |
| Estradiol (Twice Weekly) | 20 | $2,187 | $109 |
| Dotti | 11 | $2,118 | $193 |
See all 7 drugs
| Estradiol | 82 | $5,471 | $67 |
| Premarin | 13 | $5,438 | $418 |
| Yuvafem | 26 | $4,641 | $178 |
| Estradiol (Twice Weekly) | 20 | $2,187 | $109 |
| Dotti | 11 | $2,118 | $193 |
| Progesterone | 38 | $1,976 | $52 |
| Valacyclovir | 13 | $491 | $38 |
Year by year
| 2024 | 273 | 132 | None | 18% | $31,883 |
| 2023 | 200 | 92 | None | 21% | $27,416 |
| 2022 | 132 | 64 | 0% (0) | 33% | $21,461 |
| 2021 | 107 | 48 | None | 34% | $16,096 |
| 2020 | 98 | 43 | 0% (0) | 31% | $16,234 |
| 2019 | 106 | 55 | None | 29% | $16,791 |
| 2018 | 80 | 39 | 0% (0) | 28% | $12,503 |
| 2017 | 74 | 35 | None | 45% | $13,096 |
| 2016 | 66 | 33 | None | 39% | $10,036 |
| 2015 | 13 | None | None | None | $1,657 |
| 2014 | 14 | None | None | None | $386 |
| 2013 | 25 | None | None | None | $1,228 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 6 drugs
| Premarin | 15 | $7,033 | $469 |
| Estradiol | 51 | $4,985 | $98 |
| Imvexxy | 11 | $4,529 | $412 |
| Dotti | 16 | $2,709 | $169 |
| Valacyclovir | 18 | $1,350 | $75 |
| Progesterone | 19 | $1,306 | $69 |
2022: 4 drugs
| Premarin | 15 | $8,605 | $574 |
| Estradiol | 34 | $3,849 | $113 |
| Estradiol (Twice Weekly) | 16 | $2,436 | $152 |
| Progesterone | 12 | $824 | $69 |
2021: 3 drugs
| Premarin | 16 | $6,644 | $415 |
| Imvexxy | 11 | $2,698 | $245 |
| Estradiol | 23 | $2,423 | $105 |
2020: 1 drug
| Estradiol | 23 | $4,329 | $188 |
2019: 2 drugs
| Estring | 18 | $8,112 | $451 |
| Estradiol | 15 | $1,848 | $123 |
2018: 2 drugs
| Estring | 11 | $4,786 | $435 |
| Estradiol | 15 | $2,182 | $145 |
Money from drug and device companies
$34 in 2025
| 2025 | 2 | 2 | None | $34 |
| 2024 | 1 | 2 | None | $73 |
| 2023 | 1 | 3 | None | $31 |
| 2021 | 2 | 4 | None | $54 |
| 2020 | 3 | 4 | None | $52 |
| 2019 | 4 | 4 | None | $79 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Mayne Pharma Commercial | None | $18 | 1 payment
|
| CooperSurgical | Paragard T 380a | $16 | 1 payment
|
See all 2 published payments
| Mayne Pharma Commercial | Meals · 2025-06-24 | None | $18 |
| CooperSurgical | Meals · 2025-04-21 | Paragard T 380a | $16 |
See earlier years (2024, 2023, 2021, 2020, 2019)
2024: $73
| Hologic Sales and Service | Myosure Tissue Removal Device | $73 | 2 payments
|
2023: $31
| Mayne Pharma Commercial | None | $31 | 3 payments
|
2021: $54
| Avion Pharmaceuticals | Balcoltra | $38 | 3 payments
|
| TherapeuticsMD | Annovera | $16 | 1 payment
|
2020: $52
| Avion Pharmaceuticals | Balcoltra | $27 | 2 payments
|
| Allergan | Lo Loestrin Fe | $12 | 1 payment
|
| AMAG Pharmaceuticals | Vyleesi | $12 | 1 payment
|
2019: $79
| Hologic | Thinprep | $23 | 1 payment
|
| GlaxoSmithKline | Bexsero | $21 | 1 payment
|
| Merck Sharp & Dohme | Nuvaring | $19 | 1 payment
|
| TherapeuticsMD | Imvexxy | $16 | 1 payment
|
Professional record
- NPI
- 1215281019
- Licence
- CA 20A12407
- Trained
- West Virginia School of Osteopathic Medicine, 2011 · 15 years ago
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207V00000X (207V00000X)
- Mailing address
- 9 Commercial Blvd, Suite 200, Novato, CA, 94949
- NPI first listed
- 2012-10-31
- NPI last updated
- 2015-09-08
This is when the NPI record was last certified, not a medical board exam.